Lundberg, Arian http://orcid.org/0000-0002-6630-2787
Lindström, Linda S.
Parker, Joel S. http://orcid.org/0000-0003-2080-6901
Löverli, Elinor
Perou, Charles M. http://orcid.org/0000-0001-9827-2247
Bergh, Jonas
Tobin, Nicholas P. http://orcid.org/0000-0003-2343-9772
Funding for this research was provided by:
Iris, Stig och Gerry Castenbäcks Stiftelse for cancer research;
Susan G. Komen (SAC-160074)
Breast Cancer Research Foundation
NCI Breast SPORE program
Stiftelsen Konung Gustaf V:s Jubileumsfond
Cancerfonden
Vetenskapsrådet
BRECT; Cancer Society in Stockholm Personalised Cancer Medicine (PCM); Swedish Breast Cancer Association;
Article History
Received: 16 April 2020
Revised: 4 June 2020
Accepted: 10 June 2020
First Online: 24 June 2020
Compliance with ethical standards
:
: JB has no conflict of interest related to the present work. Unrelated to the present work, he received research funding from Merck paid to Karolinska Institutet and from Amgen, Bayer, Pfizer, Roche and Sanofi-Aventis paid to Karolinska University Hospital. No personal payments. Payment from UpToDate for a chapter in breast cancer prediction paid to Asklepios Medicine AB. CMP is an equity stockholder, and consultant, for of BioClassifier LLC. CMP and JP are also listed as inventors on patents on the Breast PAM50 Subtyping assay. All remaining authors have declared no conflicts of interest.